Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer May 11, 2020 SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced... Continue Reading
Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC April 6, 2020 More Than 25,000 People in Japan Are Eligible for Genetic Testing SALT LAKE CITY, April 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a lea... Continue Reading
Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer March 30, 2020 SALT LAKE CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced it ... Continue Reading
NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer March 18, 2020 Prolaris One of Only Two Prognostic Tests Recommended for Expanded Indications SALT LAKE CITY, March 18, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:... Continue Reading
A Message From Myriad About COVID-19 March 16, 2020 In light of the public health preparedness efforts currently underway, Myriad’s top priorities are protecting the health and safety of employees, our customer... Continue Reading
Welcome Patients March 4, 2020 Myriad Oncology has a suite of genetic tests to help you better understand your cancer diagnosis. Myriad’s tests may provide insight into why you may have dev... Continue Reading
Welcome Providers March 4, 2020 Welcome to the new Myriad Oncology website! For over 25 years, we have been dedicated to giving healthcare providers and patients answers they can trust. From h... Continue Reading
New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy February 14, 2020 New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy SALT LAKE CITY, Feb. 14, 202... Continue Reading
Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer February 11, 2020 Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer SALT LAKE CITY, Feb. 11, 2020 (GLOBE NEWSWIR... Continue Reading
Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer January 22, 2020 Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer SALT LAKE CITY, Jan. 22, 2020 (GLOBE NEWSWIRE) --... Continue Reading